BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1921 related articles for article (PubMed ID: 23932184)

  • 1. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Shen L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2013 Sep; 9(5):e111-94. PubMed ID: 23932184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2012 Feb; 8(1 Suppl):S1-68. PubMed ID: 22047634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Cedarbaum J; Green RC; Harvey D; Jack CR; Jagust W; Luthman J; Morris JC; Petersen RC; Saykin AJ; Shaw L; Shen L; Schwarz A; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2015 Jun; 11(6):e1-120. PubMed ID: 26073027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative.
    Weiner MW; Veitch DP
    Alzheimers Dement; 2015 Jul; 11(7):730-3. PubMed ID: 26194308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
    Hampel H; Bürger K; Teipel SJ; Bokde AL; Zetterberg H; Blennow K
    Alzheimers Dement; 2008 Jan; 4(1):38-48. PubMed ID: 18631949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current topics about mild cognitive impairment (MCI)].
    Yamamoto Y
    Seishin Shinkeigaku Zasshi; 2011; 113(6):584-92. PubMed ID: 21815470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.
    Trojanowski JQ; Vandeerstichele H; Korecka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter WZ; Weiner MW; Jack CR; Jagust W; Toga AW; Lee VM; Shaw LM;
    Alzheimers Dement; 2010 May; 6(3):230-8. PubMed ID: 20451871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2017 Apr; 13(4):e1-e85. PubMed ID: 28342697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.
    Meyer PF; Pichet Binette A; Gonneaud J; Breitner JCS; Villeneuve S
    JAMA Neurol; 2020 Apr; 77(4):508-516. PubMed ID: 31961372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating ADNI results into Alzheimer's disease drug development programs.
    Cummings JL
    Neurobiol Aging; 2010 Aug; 31(8):1481-92. PubMed ID: 20447734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau.
    Dickerson BC; Wolk DA;
    Front Aging Neurosci; 2013; 5():55. PubMed ID: 24130528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans.
    Saykin AJ; Shen L; Yao X; Kim S; Nho K; Risacher SL; Ramanan VK; Foroud TM; Faber KM; Sarwar N; Munsie LM; Hu X; Soares HD; Potkin SG; Thompson PM; Kauwe JS; Kaddurah-Daouk R; Green RC; Toga AW; Weiner MW;
    Alzheimers Dement; 2015 Jul; 11(7):792-814. PubMed ID: 26194313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing peripheral DNA methylation differences in the Alzheimer's Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease.
    Vasanthakumar A; Davis JW; Idler K; Waring JF; Asque E; Riley-Gillis B; Grosskurth S; Srivastava G; Kim S; Nho K; Nudelman KNH; Faber K; Sun Y; Foroud TM; Estrada K; Apostolova LG; Li QS; Saykin AJ;
    Clin Epigenetics; 2020 Jun; 12(1):84. PubMed ID: 32539856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of the longitudinal changes in multiple cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers on converter and non-converter Alzheimer's disease subjects with consideration for their amyloid beta status.
    Morar U; Izquierdo W; Martin H; Forouzannezhad P; Zarafshan E; Unger E; Bursac Z; Cabrerizo M; Barreto A; Vaillancourt DE; DeKosky ST; Loewenstein D; Duara R; Adjouadi M
    Alzheimers Dement (Amst); 2022; 14(1):e12258. PubMed ID: 35229014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
    J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Alzheimer's disease neuroimaging initiative: progress report and future plans.
    Weiner MW; Aisen PS; Jack CR; Jagust WJ; Trojanowski JQ; Shaw L; Saykin AJ; Morris JC; Cairns N; Beckett LA; Toga A; Green R; Walter S; Soares H; Snyder P; Siemers E; Potter W; Cole PE; Schmidt M;
    Alzheimers Dement; 2010 May; 6(3):202-11.e7. PubMed ID: 20451868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers.
    Nho K; Kueider-Paisley A; Ahmad S; MahmoudianDehkordi S; Arnold M; Risacher SL; Louie G; Blach C; Baillie R; Han X; Kastenmüller G; Trojanowski JQ; Shaw LM; Weiner MW; Doraiswamy PM; van Duijn C; Saykin AJ; Kaddurah-Daouk R;
    JAMA Netw Open; 2019 Jul; 2(7):e197978. PubMed ID: 31365104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 97.